<DOC>
	<DOCNO>NCT02256696</DOCNO>
	<brief_summary>Assess mycobactericidal activity PA-824 ( give 200 mg daily ) add first-line TB treatment ( isoniazid , pyrazinamide , rifamycin antibiotic ) 12 week treatment . Funding Source - FDA OOPD</brief_summary>
	<brief_title>Assessing PA-824 Tuberculosis ( APT Trial )</brief_title>
	<detailed_description>Phase IIB , 12-week , open-label , single-site , randomized clinical trial three treatment group . Patients drug-sensitive TB receive daily isoniazid pyrazinamide 8 week follow 4 week daily isoniazid . In addition , Arm 1 participant receive PA-824 200 mg daily rifampin 600 mg daily 12 week . Arm 2 participant receive PA-824 200 mg daily rifabutin 300 mg daily 12 week . Arm 3 participant ( control group ) receive rifampin 12 week ethambutol 8 week . Patients screen within 1 week TB diagnosis , receive 12 week study treatment return follow-up visit 4 , 12 , 36 week study treatment completion . All patient refer local TB treatment program completion study treatment finish 24-week TB treatment course .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Tuberculosis , Pulmonary</mesh_term>
	<mesh_term>Rifampin</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Pyrazinamide</mesh_term>
	<mesh_term>Ethambutol</mesh_term>
	<criteria>1 . Suspected pulmonary tuberculosis acidfast bacillus stain smear expectorate sputum Gene Xpert positive sputum sample . Patients extrapulmonary manifestation tuberculosis , addition smearpositive pulmonary disease , eligible enrollment . 2 . No prior history tuberculosis disease tuberculosis treatment 3 . Age &gt; 18 year 4 . Weight ≥ 40 kg ≤ 80 kg 5 . Karnofsky score least 60 ( require occasional assistance able care his/her need ) 6 . Signed informed consent 7 . HIV negative , positive CD4 ≥350 cells/cu mm currently take plan take combination antiretroviral therapy HIV study . 8 . Ability adhere study followup 9 . Agrees adhere contraceptive requirement 1 . Pregnant breastfeed 2 . Known intolerance allergy study drug 3 . Concomitant disorder condition isoniazid , rifampin , rifabutin , pyrazinamide , ethambutol contraindicate . These include severe hepatic damage , acute liver disease cause , allergy drug , acute uncontrolled gouty arthritis . 4 . Current plan therapy , intensive phase TB therapy cyclosporine tacrolimus , unacceptable interaction rifamycins . 5 . Any medical psychosocial condition , , view study investigator , make study participation inadvisable . 6 . Pulmonary silicosis 7 . Central nervous system TB 8 . ECG screen QTc ( Fridericia correction ) interval &gt; 450 m clinicallysignificant , opinion investigator , ECG abnormality 9 . History and/or presence ( evidence ) neuropathy epilepsy . 10 . History lens opacity evidence lens opacity slit lamp ophthalmologic examination value 1.0 high AREDS2 Clinical Lens Opacity Classification Grading System scale . 11 . Infection isolate know resistant firstline TB drug ( example , patient Gene Xpert screen local TB program result suggest resistance rifampin ) 12 . Laboratory parameter do , 14 day prior , screen ( result available review study personnel ) demonstrate follow : Serum alanine aminotransferase ( ALT ) activity &gt; 3 time upper limit normal Serum total bilirubin level &gt; 2 time upper limit normal Serum creatinine great upper limit normal Hemoglobin level le 7.0 g/dL Platelet count less 100,000/mm3 Positive pregnancy test ( woman childbearing potential )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>